Skip to main content
2025 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Listen Now

Bioanalytics
Partner Presentation

To Hybridize or Not to Hybridize: That is the Question

Monday, November 10, 2025
11:00 AM - 12:00 PM CT
Location:360 Stage #4, Exhibit Hall

Sponsored By 
Bioanalytics Partner Presentation-Bioanalytics

    Partner Presentation Speaker(s)

  • Elizabeth Dodson, PhD

    Director, Indianapolis Bioanalysis Laboratories
    IQVIA Labs
    Indianapolis, Indiana

Description:

Description: In a lab with both ligand binding and IA-LCMS capabilities, using the right tool for the study goal is essential for success when an assay can be developed for either platform. We will present case studies for each style of assay and discuss how to go about making the decision by weighing advantages and disadvantages in context of the study needs.

Learning objectives:
• How to assess study needs to select an LBA platform or pursuing IA-LCMS
• Understanding the advantages and disadvantages to both platforms – focusing not on what can be done, but what should be done.
• Seamless fluidity between LBA and LCMS groups in a single lab can offer the best experience for sponsors in need of direction and broadens the scientific expertise for any new project when a clear path is not pre-determined.

Learning Objectives:

  • How to assess study needs to select an LBA platform or pursuing IA-LC-MS
  • Understanding the advantages and disadvantages to both platforms – focusing not on what can be done, but what should be done.
  • Integrating LBA and LC-MS teams in one lab enhances sponsor support and expands scientific insight, especially when project direction is unclear, ensuring flexibility and expertise from the start.